FF 
3- 
4. 
5. 
6 . 
7. 
i 8. 
9. 
10 . 
' 
] 
11 . 
I 
13. 
! 14- 
! 15 . 
17. 
18. 
19. 
20 . 
Chong ASF. Hersh EM, Grimes WJ. Blocking of lymphokine aerivaxed killer (LAJK) cell mediated 
cytotoxicity by cell sized beads bearing tumor cell proteins, J Immunol 141(12):4418-4424, 1988. 
Chong ASF. Scuderi. P. Grimes WJ, Hersh EM. Tumor targets stimulate IL-2 activated killer cells to 
produce luterferou-g and tumor necrosis factorl. J Immunol 142x2133-2139, 1989. 
Hersh EMC. Scuderi P. Grimes WJ. Chong A Brailey JL, Gschwind CR. Salmon SE. Cytostatic and 
‘ cytotoxic activity of lymphokinc activated killer (LAK) erTT superxrarants. Cancer Immunol 
Immunother 30(l);65-70. 1989. 
Hersh EM, Murray JL, Hong WK, Rosenblum MG, Rneben JM. WeUbacdicr R, Sarwal AK, Bradley 
EQ. Arnett FCL Phase I study of cancer therapy with recombinant intedenkm-2 administered by 
intravenous bolus injection. Biotherapy L215-226. 1989. 
Schwartz JE. Scnded P, Wiggins C, Rudolph A Hersh EMI A phape I trial of recombinant tumor 
necrosis factor (rTNF) administered by continnons intravenous infusion in patients with disseminated 
malignancy. Biotherapy 11207-214, 3989. 
Hersh EMC, Funk CY. Petersen EA MosierDE and the Ditiocarb Study Group. Biological activity of 
diethyldithlocarbamaxe (Didocarb. Imnthiol^-) in an animal model of ictroyirns-indnced 
immrmndrHrdenry disease and in- elmiraT friricin patients withHEV Inf^-dnn Develop BinT Sf-an^n^ 
72-355-363, 1990 
Hersh EMC. Brewton G. Abrams D, Battle tt I. Galpin I. Gill P. Gorter R, Gotdleb M. Jonikas J, 
Landesman S. Levine A Marcel A Petersen: EA, Whiteside M, ZahradnBc T. Negron C. Boudde F, 
Caraox J. Dupuy JM. Salmi LR. Didocarb sodium (dicthylditfalocarbamatc) therapy in patients with 
symptomatic HIV infccdon and AIDS. A randomized double-blind placebo-controlled muldcenter 
smdy. JAMA 265:1538-1544, 1991. 
Hersh EM, Funk, CY. Ryschon KL, Petersen EA Mosicr DE. Effective therapy of the LP-BM5 
murine retro virus-indneed lymphoprolifcrativc immunodeficiency disease with 
diethyldithlocarbamaxe. AIDS Research and Human Retroviruses 7:553-561, 1991. 
Hersh EMC, Mctch BS, Muggia FM, Brown TD, Whitehead RP. Budd GT. Rinehart JJ, Crawford ED. 
Bonnet JD, Behrens BC. Phase H studies of recombinant human tumor necrosis factor alpha 
(thuTNFa) in patients with malignant disease. J Imm unotherapy 10:426-43 1, 199 1 
Lake D, Kawamufa T, Tomlyama T. Masuho Y, Matsumoto Y, Robinson, Jr. WE, HERSH 
EMLGenerarion and Characterization of a human monoclonal antibody that neutralizes diverse HTV- 
1 isolates in vitro. Current Science, AIDS, 6:1724, 1992. 
Taylor CW, Chase EM, Whitehead RP, Rinehart JJ, Neidhart JA, Gonzalez R. Bunn PA HERSH 
EM: A southwest oncology group phase I study of the sequential combination of recombinant 
interferon-y and recombinant mterieukin-2 in patients with cancer. J Immunotherapy, 11:176-183, 
1992. 
Verdi CJ, Taylor CW. Crogan MK. Dalke P, Meyskens FL. HERSH EMC: Phase I study of low-dose 
cyclosphosphamide and recombinant interieukin-2 for the treatment of advanced cancer. J 
Immunotherapy, 11:286-291, 1 992. 
Funk CY, Eisman J. Hersh FM: Treatment of the murine, retrovirus-induced lymphoproliferative 
immunodeficiency disease (LP-BM5) in C57BL/10 mice with the immunomodularor imexon. AIDS 
Research and Human Retiro viruses, 8:633-638, 1992. 
HERSH EMC, Gschwind C, Taylor CW, Dorr RT, Taetle R and Salmon SE: And proliferative and 
anti-tumor activity of the cyanoaziridme compound imexon on tumor cell lines and fresh tumor cells 
in-vitro. JNOC, 84:1238-1244, 1992. 
HERSH EM, Grogan TM, F unk CY and Taylor CW : Suppression of h uma n, lymphoma 
development in the SC11J mouse by imexon therapy. J Immunotherapy, 13:77-83, 1993. 
HERSH EMRFunk CY, Petersen EA Ryschon KL and Mosier, DE: Dose response and timing 
effects in the therapy of the LP-BM5 murine, retrovirus induced lymphoproliferative 
immunodeficiency disease yrith diethyldithiocaibamate. Int J Immunopharmac, 15:137-143, 
Barbuto JAM, Verastegui EL and HERSH EMs The use of transformed T cell lines for clonal 
expansion of human B cells from peripheral blood, spleen and tumor infiltrating lymphocytes. 
Hybridoma. 12:115-125, 1993. 
Punt CJA Barbuto JAM, Grimes WJ, and HERSH EM: And-tnmor antibody production by 
tumor-infiltrating (TDBL) and peripheral blood (PBBL) human B lymphocytes. Cancer Research. 
(Submitted). 
Dorr RT, Liddil JD, Dalton WS, Galler L, and HERSH EM: The 2 cyanoariridine derivative 
imexon induces protein-associated DNA-singlc strand breaks in h uman 8226 myeloma cells. 
Cancer Research. (Submitted!. 
Recombinant DNA Research, Volume 20 [627] 
